EPM News Update
Exostar has announced significant milestones in the adoption of its community cloud access and collaboration service offering for the life sciences industry. Led by two of the ten largest global pharmaceutical companies, more than 500 organisations supporting over 10,000 individuals in 46 countries on six continents are leveraging Exostar’s Life Sciences Identity Hub and Secure Access Manager (SAM) to safely, securely and cost-effectively collaborate in the cloud.
Exostar’s solutions are an enabler that supports the transformation of the drug R&D process. Rather than go it alone, companies are embracing a partner-centric R&D model that speeds time-to-market for new drugs and therapies. Exostar’s community offering in the cloud addresses three key business tenets:
• connect once (to access applications across enterprise boundaries)
• collect once (to share partner attribute information with relying parties)
• certify once (to reduce the cost of multiple audits).
The Exostar Life Sciences Identity Hub brings together organisations and their systems, applications and information. The cloud-based Identity Hub, delivered as-a-service, eliminates the need for companies, including manufacturers, CROs and academic institutions, to establish and maintain costly, redundant point-to-point interactions, freeing critical IT resources and budgets.
SAM provides employees of connected organisations with single sign-on access, using their existing credentials, to a growing list of more than 20 enterprise-class applications both on-premise and in the cloud. SAM controls user access through strong authentication of identities, along with enforcement of the roles and privileges assigned and updated by system, application and information owners.
Exostar teams with stakeholders in the community to define and refine the Life Science Identity Hub’s processes, rules and governance terms that provide the flexibility and accountability necessary to ensure compliance with corporate, industry and Government regulatory requirements while protecting intellectual property and sensitive information from compromise. The life sciences service offering builds on Exostar’s expertise in delivering similar capabilities to the aerospace and defense marketplace, where the community encompasses nearly 100,000 organisations and 300,000 users in 150 countries.
“Our solution is allowing life sciences organisations to more quickly establish new relationships, strengthen existing relationships and reduce IT costs,” said Vijay Takanti, Exostar’s Vice President of Security and Collaboration Solutions. “By reducing the time it takes these organisations to begin collaborating productively with their external partners from months to days, we are helping streamline the drug R&D process — driving new revenue streams for our customers while bringing life-altering drugs and therapies to market sooner.”
Exostar, +1 703 793 7800, www.exostar.com.